CNS Pharmaceuticals Files S-1 for Future Offering
Ticker: CNSP · Form: S-1 · Filed: 2024-06-10T00:00:00.000Z
Sentiment: neutral
Topics: s-1, registration, pharmaceuticals, capital-raise
TL;DR
CNS Pharma filed an S-1, looks like they're raising cash soon.
AI Summary
CNS Pharmaceuticals, Inc. filed an S-1 registration statement on June 7, 2024, for an unspecified offering. The company, incorporated in Nevada with its principal executive offices in Houston, TX, operates in the pharmaceutical preparations sector. This filing indicates a potential future sale of securities to raise capital.
Why It Matters
This S-1 filing signals CNS Pharmaceuticals' intent to raise capital, which could fund its drug development pipeline or operational expansion.
Risk Assessment
Risk Level: medium — S-1 filings often precede capital raises, which can be dilutive or signal financial needs, but the specific terms and purpose are not yet detailed.
Key Numbers
- 2834 — SIC Code (Pharmaceutical Preparations industry)
- 822318545 — IRS Number (Employer Identification Number)
Key Players & Entities
- CNS Pharmaceuticals, Inc. (company) — Registrant
- June 7, 2024 (date) — Filing Date
- Nevada (jurisdiction) — State of Incorporation
- Houston, TX (location) — Principal Executive Offices
- John Climaco (person) — Chief Executive Officer
- 333-280074 (registration_number) — SEC File Number
FAQ
What is the purpose of this S-1 filing?
The S-1 filing is a registration statement required by the SEC before a company can offer its securities to the public, indicating an intent to raise capital, though the specific amount and terms are not detailed in this initial filing.
When was this S-1 filing submitted?
The S-1 filing was submitted to the SEC on June 7, 2024.
Where is CNS Pharmaceuticals, Inc. headquartered?
CNS Pharmaceuticals, Inc. is headquartered in Houston, TX, with its principal executive offices located at 2100 West Loop South, Suite 900.
What industry does CNS Pharmaceuticals, Inc. operate in?
CNS Pharmaceuticals, Inc. operates in the Pharmaceutical Preparations industry, as indicated by its SIC code 2834.
Who is the CEO of CNS Pharmaceuticals, Inc.?
Mr. John Climaco is the Chief Executive Officer of CNS Pharmaceuticals, Inc.
Filing Stats: 4,720 words · 19 min read · ~16 pages · Grade level 14.1 · Accepted 2024-06-07 19:53:03
Key Financial Figures
- $5.35 — sumed combined public offering price of $5.35 per share and accompanying common warra
- $0.001 — mmon stock and has an exercise price of $0.001 per share. The combined purchase price
- $5 — ccompanying common warrants is equal to $5.349, which is equal to the combined pur
- $750,000 — eed to pay HPI: (i) development fees of $750,000 over a three-year period beginning Nove
- $50,000 — (ii) a 2% royalty on net sales; (iii) a $50,000 per year license fee; (iv) milestone pa
- $100,000 — license fee; (iv) milestone payments of $100,000 upon the commencement of a Phase II tri
- $1.0 million — he commencement of a Phase II trial and $1.0 million upon the approval of a New Drug Applica
- $1,134,000 — he Company agreed to fund approximately $1,134,000 over a two-year period. The Company pai
- $334,000 — r period. The Company paid and recorded $334,000 in 2020 related to this agreement in re
- $800,000 — statements of operations. The remaining $800,000 was paid in 2021. The principal investi
Filing Documents
- cns_s1.htm (S-1) — 348KB
- cns_ex0101.htm (EX-1.1) — 54KB
- cns_ex0413.htm (EX-4.13) — 98KB
- cns_ex0414.htm (EX-4.14) — 98KB
- cns_ex0415.htm (EX-4.15) — 99KB
- cns_ex0501.htm (EX-5.1) — 16KB
- cns_ex1023.htm (EX-10.23) — 261KB
- cns_ex2301.htm (EX-23.1) — 3KB
- cns_ex107.htm (EX-FILING FEES) — 32KB
- image_001.jpg (GRAPHIC) — 3KB
- image_002.jpg (GRAPHIC) — 2KB
- image_003.jpg (GRAPHIC) — 43KB
- 0001683168-24-004062.txt ( ) — 1452KB
- cnsp-20240607.xsd (EX-101.SCH) — 3KB
- cnsp-20240607_lab.xml (EX-101.LAB) — 34KB
- cnsp-20240607_pre.xml (EX-101.PRE) — 22KB
- cns_s1_htm.xml (XML) — 3KB
RISK FACTORS
RISK FACTORS 5 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS 11
USE OF PROCEEDS
USE OF PROCEEDS 12
DILUTION
DILUTION 13 CAPITALIZATION 15
DESCRIPTION OF CAPITAL STOCK
DESCRIPTION OF CAPITAL STOCK 16 DESCRIPTION OF PRE-FUNDED WARRANTS 19 DESCRIPTION OF COMMON WARRANTS 20 PLAN OF DISTRIBUTION 23 LEGAL MATTERS 25 EXPERTS 25 INCORPORATION OF CERTAIN INFORMATION BY REFERENCE 26 WHERE YOU CAN FIND MORE INFORMATION 26 i ABOUT THIS PROSPECTUS This prospectus is part of a registration statement on Form S-1 that we filed with the SEC to register the securities offered hereby under the Securities Act. We may also file a prospectus supplement or post-effective amendment to the registration statement of which this prospectus forms a part that may contain material information relating to these offerings. We incorporate by reference important information into this prospectus. You may obtain the information incorporated by reference without charge by following the instructions under " Where You Can Find More Information ." You should carefully read this prospectus as well as additional information described under " Incorporation of Certain Information by Reference ," before deciding to invest in our securities. We have not, and the placement agents have not, authorized anyone to provide any information or to make any representations other than those contained in this prospectus or in any free writing prospectuses prepared by or on behalf of us or to which we have referred you. We take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. This prospectus is an offer to sell only the securities offered hereby, and only under circumstances and in jurisdictions where it is lawful to do so. The information contained in this prospectus or in any applicable free writing prospectus is current only as of its date, regardless of its time of delivery or any sale of our securities. Our business, financial condition, results of operations and prospects may have changed since that date. For investors outside the United States: We have not, and the placement a